Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Consensus Price Target of $4.00

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $4.00.

A number of brokerages recently weighed in on TNYA. Weiss Ratings upgraded shares of Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Wall Street Zen upgraded shares of Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 6th.

Tenaya Therapeutics Stock Down 0.3%

TNYA stock opened at $0.56 on Wednesday. Tenaya Therapeutics has a twelve month low of $0.53 and a twelve month high of $2.35. The firm has a market cap of $126.49 million, a price-to-earnings ratio of -1.06 and a beta of 2.87. The business’s fifty day simple moving average is $0.69 and its two-hundred day simple moving average is $0.74.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $10.00 million. Research analysts expect that Tenaya Therapeutics will post -0.38 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TNYA. Mirador Capital Partners LP increased its stake in shares of Tenaya Therapeutics by 2.0% during the second quarter. Mirador Capital Partners LP now owns 905,097 shares of the company’s stock valued at $669,000 after buying an additional 18,180 shares during the period. Spark Investment Management LLC purchased a new position in Tenaya Therapeutics in the second quarter valued at about $26,000. Integrity Wealth Solutions LLC purchased a new position in Tenaya Therapeutics in the first quarter valued at about $27,000. Callan Family Office LLC bought a new position in Tenaya Therapeutics in the second quarter worth about $37,000. Finally, Castleview Partners LLC purchased a new position in Tenaya Therapeutics in the first quarter worth $106,000. Institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular diseases. The company uses gene therapy, gene editing and small-molecule approaches to address the underlying causes of inherited and acquired heart conditions rather than treating symptoms alone.

Tenaya’s product candidates include TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathy.